Hyaluronic Acid Dermal Filler for Inducing Mechanical Ptosis in Facial Nerve Palsy: A Novel Approach to Treat Exposure Keratopathy

TL;DR

This study shows that hyaluronic acid dermal fillers can safely and effectively reduce eyelid issues in facial nerve palsy patients, protecting the cornea.

Contribution

Introduces hyaluronic acid dermal fillers as a novel, minimally invasive treatment for exposure keratopathy in facial nerve palsy.

Findings

A 0.3 ml injection reduced lagophthalmos from 5.5 mm to 0.8 mm and lasted 24 weeks.

No adverse effects were observed during the 24-week follow-up period.

The method offers a cost-effective alternative to traditional surgical treatments.

Abstract

This study aimed to assess a dermal filler’s safety, efficacy, and outcome for inducing temporary mechanical ptosis of the upper eyelid in patients with facial nerve palsy with exposure keratopathy.

A prospective interventional study was conducted on 13 patients with facial nerve palsy with various levels of lagophthalmos and exposure keratopathy. A total of 0.3 ml of dermal filler (Juvéderm Ultra Plus XC, Allergan, USA) was injected subdermally over the pretarsus area of the upper lid to induce mechanical ptosis. Post-dermal filler implantation patients were followed up for a reduction in the amount of lagophthalmos and adverse effects.

Out of 13 patients exposed to keratopathy due to facial nerve palsy, two were females, and eleven were males, with a mean age of 54+/-6.5 years and House Brackmann severity grades IV and V. The preinjection average lagophthalmos was 5.5 mm, and it decreased to an average of 0.8 mm postinjection at 1 week of follow-up, which was maintained at 12 weeks and 24 weeks of follow-up. No adverse side effects were observed during the 24-week follow-up.

Discussion: This study highlights the effectiveness and safety of hyaluronic acid-based dermal fillers in treating lagophthalmos and exposure keratopathy caused by facial nerve palsy. A single 0.3 ml injection in the pretarsal region successfully induced mechanical ptosis, significantly reducing lagophthalmos and protecting the cornea, with results sustained for 24 weeks and no adverse effects. Offering a minimally invasive, cost-effective alternative to traditional surgical methods, dermal fillers show promise, particularly in early-stage management. Despite a small sample size and limited follow-up, these findings pave the way for future research to refine dosing and assess long-term efficacy.

Absorbable dermal filler implants are an easy and effective method for inducing mechanical ptosis and protecting the cornea in patients with exposure keratopathy due to facial nerve palsy.

Figures